Viridian Therapeutics Q3 2026 Earnings Call - VIRIDIAN THERAPEUTICS INC

Financial Performance:

• Generated $24.7 million in net product revenue in the first quarter of the Lomboa launch.
• Reported over 100 patients initiating therapy and completing at least one infusion by the end of the quarter.
• Ended the quarter with $955 million in cash, cash equivalents, and marketable securities.
• Revenue recognition occurs upon receipt by specialty distributors; extended payment terms were offered to infusion centers pending the permanent J-code, impacting accounts receivable but not revenue recognition timing.
• Cash position is deemed sufficient to fund current business plans through profitability.

Guidance and Future Outlook:

• Management declined to provide specific Q4 revenue or patient volume guidance, citing the early stage of the launch.
• Anticipates continued growth into Q4 due to the high volume of patient starts occurring late in Q3.
• Projects broad payer coverage (critical mass) to be achieved within 6 to 9 months from launch, reaching the majority of covered lives in the U.S.
• Timeline remains on track to submit the BLA for AllegraBART (ELLi) in Q1 2027.
• Permanent J-code for Lomboa was assigned by CMS and will become effective January 1, 2027.

Business Segments and Product Lines:

• Lomboa (Thyroid Eye Disease): First commercial quarter exceeded expectations; product profile features rapid symptom improvement (as early as 3 weeks) and a short 12-week course requiring only five infusions.
• Pipeline (ELLi): Next-generation subcutaneous anti-IGF-1R designed for home self-administration as infrequently as every eight weeks, leveraging the same launch infrastructure as Lomboa.
• Pipeline (VRDN-292): Anti-TSHR candidate aiming for "best-in-class" status; Phase 1 trial in Graves' disease patients expected to initiate later this quarter.
• Pipeline (VRDN-008): Half-life extended FcRn inhibitor; first-in-human data expected to be disclosed later this quarter.

Market and Competitive Landscape:

• Targeting the ~2,000 core prescribers who account for over 80% of all IGF-1R prescriptions in the TED market.
• Strategy focuses on conversion of existing prescribers rather than market creation, though management remains open to potential market expansion beyond the ~$2 billion historical run rate due to Lomboa's efficacy profile.
• Early data suggests a patient mix of roughly 80% active disease and 20% chronic disease, consistent with historical trends for the class.
• Payer coverage is progressing well, with 30% of covered lives having a policy in place by end of Q3, aiming for parity with competitor Tepesio.

Risks and Challenges:

• Launch trajectory is still early; management emphasizes the need to validate sustained demand over subsequent quarters to rule out initial "bolus" effects.
• Payer policy adoption timelines vary, requiring reliance on medical exception processes and patient support teams for patients without immediate policy coverage.
• Competition from established therapies remains a factor, necessitating strong field execution to maintain market share.

Management Commentary and Tone:

• Tone is highly confident and enthusiastic, describing the launch as a "strong start" and "exceptional" execution.
• Management attributes success to a "compelling product profile," a pre-built "highly experienced" field team, and rigorous pre-approval payer engagement.
• Emphasized that the launch execution is repeatable for future pipeline assets like ELLi, citing the alignment of product, people, and strategy.
• Repeatedly stressed that while results exceed internal expectations, the market dynamics require continued monitoring to confirm long-term trends.

Analyst Questions and Answers:

• Revenue Cadence: Management clarified that the $24.7M revenue is demand-driven, not inventory stocking, with most of the 100+ patients starting therapy late in the quarter.
• Patient Status: The majority of the 100 patients were initiated in the latter part of the quarter; most are early in their 5-infusion treatment course, with few having completed a full cycle.
• Payer Coverage: Confirming progress toward 90% covered lives in pre-launch meetings, with 30% of covered lives having active policies by quarter-end; goal is broad coverage by Q2/Q3 2027.
• Prescriber Behavior: Observations include both clinicians experimenting with new patients and established prescribers switching their IGF-1R volume to Lomboa; targeting the core 2,000 prescribers.
• Market Share: While early metrics suggest significant uptake, management declined to comment on specific market share percentages, preferring to track patient start volumes.
• J-Code Impact: The temporary period without a permanent J-code necessitated flexible payment terms for infusion centers, but revenue is recognized upon delivery to distributors.

Other Key Points:

• Viridian Cares: The patient support services team is a critical differentiator, facilitating enrollment, navigation, and access for patients even in the absence of immediate payer policy.
• Product Differentiation: Highlighted rapid onset of action and the convenience of a short treatment course (5 infusions) as key drivers for patient and physician preference.
• Strategic Focus: The company remains focused on expanding from Thyroid Eye Disease (TED) to Graves' disease and broader autoimmune indications via its FcRn and TSHR portfolios.